Klaus Theobald, MD, PhD

Chief R&D Officer

​

Klaus Theobald, MD, PhD, has served as our Chief Research & Development Officer since our inception in January 2016.  From 2009 to 2016, Dr. Theobald was the Chief R&D Officer for Anterios until its acquisition by Allergan. Prior to that, Dr. Theobald led R&D at CollaGenex, a publicly traded US pharmaceutical company, where he developed dermatologic prescription products, including both Oracea® and Mirvaso®, until Collagenex’s acquisition by Galderma. Dr. Theobald has over 25 years of bio-pharmaceutical development experience bringing dozens of biologic and small molecule products to market, and serving in various roles in European and US companies. Dr. Theobald holds a MD and PhD from Johannes Gutenberg University in Germany.